Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population
-
By
-
Miracle Amadi
-
Simopekka Vänskä
-
Irja Davidkin
-
Heikki Haario
-
Tuija Leino
-
Merit Melin
-
Kari Auranen
-
Mia Kontio
-
May 27, 2026
-
Clinical Scorecard: Maintaining Herd Immunity for Measles: Findings from a Serological Study in a Population Without Outbreaks
At a Glance
| Category | Detail |
|---|
| Condition | Measles |
| Key Mechanisms | Herd immunity requires over 90% of the population to have immunity through vaccination or prior infection. |
| Target Population | Individuals vaccinated with the MMR vaccine, particularly in Finland. |
| Care Setting | Population-level health monitoring and vaccination programs. |
Key Highlights
- Measles R0 exceeds 10, necessitating high vaccination coverage for herd immunity.
- Sustained herd immunity observed in Finland despite low-level exposure.
- Antibody concentration of 120 mIU/ml is a correlate of protection against measles.
- Vaccinated individuals who contract measles experience milder symptoms and reduced transmission risk.
- Long-term antibody levels in vaccinated individuals show a decline over time.
Guideline-Based Recommendations
Diagnosis
- Monitor antibody levels in vaccinated individuals to assess immunity.
Management
- Ensure vaccination coverage remains above 90% to maintain herd immunity.
Monitoring & Follow-up
- Regularly assess the proportion of the population exceeding the antibody threshold for herd immunity.
Risks
- Potential resurgence of measles due to declining immunity and insufficient vaccination coverage.
Patient & Prescribing Data
Individuals vaccinated with the MMR vaccine in Finland.
Vaccination with MMR provides long-term immunity, but antibody levels may decline over time.
Clinical Best Practices
- Maintain high vaccination rates to prevent outbreaks.
- Monitor long-term antibody levels in vaccinated cohorts.
- Educate the population on the importance of vaccination for herd immunity.
Related Resources & Content
